At the 2023 JP Morgan Healthcare Conference, there is no news of large-scale M&A (mergers and acquisitions) compared to previous years, and global big pharmas are expected to introduce new products and promising pipelines in preparation for patent expiration.
According to Kiwoom Securities’ ‘JP Morgan Healthcare Conference Summary’ report, this JP Morgan Healthcare Conference, which was held face-to-face in three years, was absent from the news of a large-scale M&A between Big Pharma and Biotech. Acquisition of US biotech by European biopharmaceutical companies stood out, and demand for joint research on new modality RNA and gene editing was still high.
Johnson & Johnson (J&J)Even if Stelara’s patent expires this year, sales of the pharmaceutical division are expected to reach 60 billion dollars (approximately 74.31 trillion won) by 2025. Heo Hye-min, a researcher at Kiwoom Securities, said, “Johnson & Johnson is expected to change the paradigm from treatment to cure and secure leadership in the multiple myeloma field. .
Amgenhas faced pressure from expiring patents and issues with the Inflation Reduction Act (IRA) over the past few years, but emphasized volume-driven growth in an environment of price cuts and manufacturing facility establishment.
Researcher Heo said, “The company showed the role of the LDL-lowering agent in preventing heart attacks and strokes through a follow-up of up to 8.6 years on the PCSK9 inhibitor Repatha. It emphasized the results of Repatha’s expansion study.” The similar Amjevita will be released on the 31st of this month.”
Researcher Huh said, “Amgen has re-entered the ADC (antibody drug conjugate) field in line with market changes. To this end, it has entered into partnerships with companies such as LegoChem Bio and Sinafix,” and added, “We plan to continue investing in internal and external innovation.” added.
Pfizerpredicted at the conference, “Corona-related revenues will decrease, but we plan to create a market by combining it with the flu. Corona will become like the flu in the future.”
Researcher Heo said, “Pfizer is facing a very large patent cliff following 2025. It is very important to develop 19 new products and indications over the next 18 months. After 18 months, the pipeline will be released from the second half of 2024. “We plan to seek growth with our portfolio of oral GLP-1, gene therapy and shingles vaccine.”
Modernarevealed that last year’s corona vaccine sales recorded $ 18.4 billion (approximately 22.788 trillion won). Researcher Huh said, “Moderna has proven the efficacy of the customized cancer vaccine mRNA-4157/V940 in combination with Keytruda.” (L/I), M&A, etc.”
Merckwill leverage its leadership in oncology well into the next decade to seek advances with broad applications in cardiometabolic, vaccines, neuroscience, epidemiology and immunology. Researcher Huh said, “Merck mentioned Keytruda SC as a scientific innovation that increases patient accessibility when asked regarding the formulation timeline and role at the conference. It is especially necessary for early cancer patients because it can be used at home along with oral medications. “he said.
he is “AbbViehas secured more than 90% of its prescription drug list for Humira this year. By offsetting the impact of Humira’s patent expiry, we will return to rapid growth from 2025.”Novavaxwill lose government contracts as the corona emergency ends. The vaccine market share is expected to increase through the open vaccine market.” Novartisaims to increase the proportion of future technology platforms (cell genes, radioligand, xRNA, etc.) from the current 27% to more than 50% by 2030.
Samsung BiologicsRegarding the possibility of manufacturing monoclonal antibodies for Alzheimer’s treatment, it said that two more plants with a capacity of 180,000 liters would be needed to serve 10% of the 15 million Alzheimer’s patients in the United States. “We are expanding our portfolio of next-generation treatments (ADC, gene therapy, etc.),” he said.